Share Prices & Company Research

Market News

19 Jun 2019 | 14:47

Futura Medical recruits more than 1,000 patients for erectile dysfunction study

Futura Medical said it had completed patient recruitment for a clinical study testing the efficacy of an erectile dysfunction treatment.

Over 1,000 patients had been recruited for the study, which included around 60 centres across central and eastern Europe.

It would compare the efficacy of 0.2%, 0.4% and 0.6% doses of the treatment -- MED2005 -- against that of placebo, with an initial three-month study period for each patient.

'The company's focus is now on the Phase 3 data read-out at the end of the year, which we hope will significantly clinically de-risk MED2005, and help provide commercial partners with greater certainty around the potential opportunity it presents,' chief executive James Barder said.

At 2:47pm: (LON:FUM) Futura Medical PLC share price was +2.75p at 28.25p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.